BACKGROUND: Based on sequence variation in the UL55 gene that encodes glycoprotein B (gB), human cytomegalovirus (CMV) can be classified into four gB genotypes. Previous studies have suggested there could be an association between CMV gB genotype and clinical outcome in transplant patients. OBJECTIVES: The goal of this study was to determine the distribution of gB genotypes in a cohort of liver transplant recipients with CMV infection and the effect of gB type on clinical outcomes including CMV disease and rejection. STUDY DESIGN: DNA was extracted directly from the blood of 58 liver transplant recipients with CMV infection. The gB genotype of CMV was determined using the polymerase chain reaction to amplify a region of UL55, followed by restriction analysis based on HinfI and RsaI digestion. Results were correlated with CMV viral load, symptomatic disease, and development of acute rejection. RESULTS: The distribution of CMV gB genotypes was: gB1, 15/58 (25.9%); gB2, 16/58 (27.6%); gB3, 21/58 (36.2%); gB4, 2/58 (3.4%) and four patients (6.9%) had mixed infection. No correlation between CMV genotype and peak CMV viral load was observed. Symptomatic CMV disease developed in 25/58 (43.1%) patients and 26/58 (44.8%) had acute rejection. The rate of CMV disease and acute graft rejection in patients infected with the different CMV gB genotypes was not significantly different. However, all four patients with infection with a mixture of CMV gB genotypes developed progression to CMV disease (P=0.030). CONCLUSIONS: The gB genotype did not correlate with peak CMV viral load and with the development of CMV disease or acute rejection following liver transplantation.
BACKGROUND: Based on sequence variation in the UL55 gene that encodes glycoprotein B (gB), human cytomegalovirus (CMV) can be classified into four gB genotypes. Previous studies have suggested there could be an association between CMV gB genotype and clinical outcome in transplant patients. OBJECTIVES: The goal of this study was to determine the distribution of gB genotypes in a cohort of liver transplant recipients with CMV infection and the effect of gB type on clinical outcomes including CMV disease and rejection. STUDY DESIGN: DNA was extracted directly from the blood of 58 liver transplant recipients with CMV infection. The gB genotype of CMV was determined using the polymerase chain reaction to amplify a region of UL55, followed by restriction analysis based on HinfI and RsaI digestion. Results were correlated with CMV viral load, symptomatic disease, and development of acute rejection. RESULTS: The distribution of CMV gB genotypes was: gB1, 15/58 (25.9%); gB2, 16/58 (27.6%); gB3, 21/58 (36.2%); gB4, 2/58 (3.4%) and four patients (6.9%) had mixed infection. No correlation between CMV genotype and peak CMV viral load was observed. Symptomatic CMV disease developed in 25/58 (43.1%) patients and 26/58 (44.8%) had acute rejection. The rate of CMV disease and acute graft rejection in patients infected with the different CMV gB genotypes was not significantly different. However, all four patients with infection with a mixture of CMV gB genotypes developed progression to CMV disease (P=0.030). CONCLUSIONS: The gB genotype did not correlate with peak CMV viral load and with the development of CMV disease or acute rejection following liver transplantation.
Authors: Vincent C Emery; Oriol Manuel; Anders Asberg; Xiaoli Pang; Deepali Kumar; Anders Hartmann; Jutta K Preiksaitis; Mark D Pescovitz; Halvor Rollag; Alan G Jardine; Christoph G Gahlemann; Atul Humar Journal: J Clin Virol Date: 2012-03-10 Impact factor: 3.168
Authors: Hsuan-Yuan Wang; Sarah M Valencia; Susanne P Pfeifer; Jeffrey D Jensen; Timothy F Kowalik; Sallie R Permar Journal: Viruses Date: 2021-06-09 Impact factor: 5.818
Authors: Xuan Zhang; Ya Ping Huang; Hai Nv Gao; Mei Fang Yang; Hong Zhao; Jian Hua Hu; Xiao Ming Chen; Wei Hang Ma; Jun Fan Journal: PLoS One Date: 2012-12-10 Impact factor: 3.240
Authors: Andrea R McWhorter; Lee M Smith; Laura L Masters; Baca Chan; Geoffrey R Shellam; Alec J Redwood Journal: PLoS Pathog Date: 2013-01-03 Impact factor: 6.823
Authors: Débora C Dieamant; Sandra H A Bonon; Renata M B Peres; Claudia R C Costa; Dúlcinéia M Albuquerque; Eliana C M Miranda; Francisco J P Aranha; Gislaine Oliveira-Duarte; Virginio C A Fernandes; Carmino A De Souza; Sandra C B Costa; Afonso C Vigorito Journal: BMC Infect Dis Date: 2013-07-10 Impact factor: 3.090